Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
about
Pyruvate dehydrogenase kinase as a novel therapeutic target in oncologyDefining the sister rat mammary tumor cell lines HH-16 cl.2/1 and HH-16.cl.4 as an in vitro cell model for Erbb2PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitroMutational profiling of kinases in glioblastoma.The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in TherapyTumor angiogenesis: pericytes and maturation are not to be ignoredTreating Metastatic Breast Cancer: The Evidence for Targeted TherapyTrastuzumab-containing regimens for metastatic breast cancerEstrogen receptor alpha gene amplification in breast cancer: 25 years of debateCancer pharmacogenomics: strategies and challengesRecombinant human erythropoietin antagonizes trastuzumab treatment of breast cancer cells via Jak2-mediated Src activation and PTEN inactivationCharacterisation of HER heterodimers in breast cancer using in situ proximity ligation assayNSABP breast cancer clinical trials: recent results and future directionsAllele quantification using molecular inversion probes (MIP).Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cellsHER-2 gene amplification can be acquired as breast cancer progressesIs NF-kappaB a good target for cancer therapy? Hopes and pitfallsTargeting cellular metabolism to improve cancer therapeuticsBreast cancer in the personal genomics eraAutocrine TNFalpha signaling renders human cancer cells susceptible to Smac-mimetic-induced apoptosisInternational network of cancer genome projects.Activity of the kinesin spindle protein inhibitor ispinesib (SB-715992) in models of breast cancerThe use of lentinan for treating gastric cancerAnalysis of molecular inversion probe performance for allele copy number determinationQuercetin-induced ubiquitination and down-regulation of Her-2/neuA phase I trial of immunotherapy with lapuleucel-T (APC8024) in patients with refractory metastatic tumors that express HER-2/neuAGTR1 overexpression defines a subset of breast cancer and confers sensitivity to losartan, an AGTR1 antagonistTranscriptome sequencing to detect gene fusions in cancerThe role of HER2-targeted therapies in women with HER2-overexpressing metastatic breast cancerTamoxifen (ICI46,474) as a targeted therapy to treat and prevent breast cancerGenomic amplification of the human telomerase gene (TERC) in pap smears predicts the development of cervical cancerErbB receptors: from oncogenes to targeted cancer therapiesBiological response modifiers in cancerEffective therapy of murine models of human leukemia and lymphoma with radiolabeled anti-CD30 antibody, HeFi-1The role of the ubiquitination-proteasome pathway in breast cancer: ubiquitin mediated degradation of growth factor receptors in the pathogenesis and treatment of cancerTrastuzumab, an appropriate first-line single-agent therapy for HER2-overexpressing metastatic breast cancer25th Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, USA, 10-14 December 2002 Update on clinical researchAlphavirus replicon particles containing the gene for HER2/neu inhibit breast cancer growth and tumorigenesis.Long-term prognostic significance of HER-2/neu in untreated node-negative breast cancer depends on the method of testingDocetaxel plus cisplatin is effective for patients with metastatic breast cancer resistant to previous anthracycline treatment: a phase II clinical trial
P2860
Q21129303-53D13309-D763-448A-B05C-497770069E0FQ21134904-2F967FFC-B20D-4F11-BBF3-E054FDB3DAC8Q21195212-AFEF04D8-80EB-4924-9FCF-77725ECFA182Q21261249-8930A3D1-4268-4E95-9365-9AAE09036519Q21284978-AA2E58DD-2368-409A-8B9F-913A1F61785CQ21296683-5AD0A367-5463-4839-9683-B96CBFDDD72BQ24193683-6AE24074-3294-4902-AF98-CAC49D14A32AQ24194019-47966A5F-1E23-453E-85C9-E2CD6EA1AEDCQ24273274-22C06A2A-F230-44B6-A6C2-92B0149E3C72Q24289309-F9FE3376-755E-48A5-A7BD-1319E6187215Q24306910-10BA4DAC-6711-4D1D-81F3-C0A560D03935Q24337937-4BAB45FA-DED6-4000-87CB-10AE0BD834EFQ24520573-C970D047-FE82-4814-A73E-05A9C0262CD8Q24537476-B5DDE7FB-58D7-49BC-B463-AFCD8B4DDCD6Q24561962-77605F89-3C39-440D-8F3D-0FE90040482FQ24563115-45118B89-C610-4B38-A788-820BE41C0DF4Q24570128-AC6060CD-0875-403B-9098-9B4E4693E399Q24596727-BB2EF0AC-CEA6-4A9B-8EE1-B807CB5D7BB4Q24602679-140A4FAE-E7AF-49A5-9EDC-556FC0BDA9B3Q24609324-B62C61AA-C52A-44BD-8011-7BA89E526EE7Q24611474-702B42D9-6DCA-4706-A743-68F1B830D0AFQ24615262-52CD1160-500D-4944-A7F3-DA68126FE6B7Q24619416-4FEB927C-B2BE-45D1-9F8A-EB109EFB5ABAQ24642329-F5DAF0B6-8124-43CC-92B6-58EC042BF212Q24646978-6E6AAA29-DD4B-4AA9-8599-0B5B38375C1EQ24649530-56E6ABF7-4C16-49AE-B4C6-7E728AB3C54FQ24652842-3B8C5CBD-91AC-4DDA-B058-9A943BA3410DQ24653386-F08E8708-8177-4024-ADC2-4678A5F7651FQ24656159-8F576190-9BBD-4FDF-8B11-2965376F5F76Q24670339-09003516-A62C-4974-959E-7B928C619807Q24675639-5C174F5D-EE52-489D-B7A3-444B71C3CB50Q24683709-7A534CD9-BE9B-480D-99E1-6055166C8F81Q24685049-71DD41E8-2670-4711-A1DE-610600EEC59AQ24685212-657C8576-2343-4725-94F0-34DBB6DADAEDQ24794951-FF03D55A-9EB3-4BEA-BA3C-820F3316E36CQ24795614-82721896-A8ED-4050-90E8-553EB000BC1EQ24795656-0F9BAA97-E1EE-42DC-8DD6-72F5C2705029Q24796792-466EEC61-3608-4CAD-85D0-73A650A0A3E3Q24797752-BE155220-B676-491B-BACA-96AD7B21176FQ24799659-CBC8FD5D-57BF-4F8A-AA39-35E85AD26B36
P2860
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
description
2001 nî lūn-bûn
@nan
2001 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մարտին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Use of chemotherapy plus a mon ...... ancer that overexpresses HER2.
@ast
Use of chemotherapy plus a mon ...... ancer that overexpresses HER2.
@en
Use of chemotherapy plus a mon ...... ancer that overexpresses HER2.
@nl
type
label
Use of chemotherapy plus a mon ...... ancer that overexpresses HER2.
@ast
Use of chemotherapy plus a mon ...... ancer that overexpresses HER2.
@en
Use of chemotherapy plus a mon ...... ancer that overexpresses HER2.
@nl
prefLabel
Use of chemotherapy plus a mon ...... ancer that overexpresses HER2.
@ast
Use of chemotherapy plus a mon ...... ancer that overexpresses HER2.
@en
Use of chemotherapy plus a mon ...... ancer that overexpresses HER2.
@nl
P2093
P3181
P1476
Use of chemotherapy plus a mon ...... ancer that overexpresses HER2.
@en
P2093
A Bajamonde
B Leyland-Jones
D J Slamon
W Eiermann
P304
P3181
P356
10.1056/NEJM200103153441101
P407
P577
2001-03-15T00:00:00Z